Osteomyelitis and Device-Related Orthopaedic Infection
According to the HCUP database, approximately 325,000 cases of osteomyelitis (bone infection) and another 75,000 orthopaedic device-related infections were treated in the US in 2014. Compared to SSIs in general, these infections are especially serious and costly to treat due to the involvement of bone and foreign bodies. Bacteria can rapidly colonize and establish biofilm on implant surfaces, leading to a persistent and virulent infection.
The current standard of care for treatment of these infections includes surgical removal of all infected tissue and hardware, and local antibiotic delivery to eradicate any remaining biofilm. Reconstruction of the surgical site is delayed until after the infection has been controlled. Treatment success rates reported in the literature vary considerably, between 40 and 100%.
SBG002 may enable effective treatment of orthopaedic infections in one procedure by providing effective local antimicrobial delivery sufficient to kill any remaining biofilm based bacteria, preventing recurrence of the infection. This would enable a new standard of care in many cases, eliminating the additional morbidity and cost of the second stage.